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The use of humidified high-flow nasal cannulae (HHFNC) as an alternative mode of 
non-invasive ventilation (NIV) in neonates has become widespread. A survey of UK 
neonatal units showed the proportion using HHFNC had increased from 56% in 2012 to 
87% in 2015 (1).   A recently reported Cochrane Review (2) comparing the use of 
HHFNC against other NIV modes of ventilation immediately after birth or following 
extubation showed no significant difference in the rates of bronchopulmonary dysplasia 
(BPD) or death and no significant difference in the rates of treatment 
failure/reintubation. Benefits cited include a significantly reduced risk of nasal trauma 
as compared to continuous positive airway pressure (CPAP).  Furthermore, both 
medical staff and parents (3) were found to prefer HHFNC to CPAP.  Identification of 
infants in whom use of HHFNC as either a primary or step-down mode of respiratory 
support may be inappropriate might further reduce the failure rate of HHFNC. 
 
We carried out a retrospective analysis of all infants treated with HHFNC admitted to 
the neonatal unit of King’s College Hospital NHS Foundation Trust (London, UK) 
between 01/01/2015 and 31/12/2016. Our aim was to identify the clinical and 
demographic characteristics that might contribute to failure of support by HHFNC. 
Failure was defined as the need to switch to CPAP or intubation and mechanical 
ventilation (MV) for recurrent episodes of apnoea, development of a respiratory 
acidosis (pH<7.25 and pCO2>8 kPa) or an inspired oxygen concentration (FiO2) 
requirement > 0.6. Success was defined as weaning off all respiratory support or 
weaning to supplemental oxygen delivered by low-flow nasal cannulae.  In infants who 
had had multiple episodes of support using HHFNC, only the first episode was 
reviewed. The episode of HHFNC was defined as primary if HHFNC was the primary 
method of respiratory support used or a step-down episode if it was following from 
CPAP or MV.  
 
3 
 
Two hundred and twenty-six infants were identified from whom 134 complete records 
were available for use. Out of the 134, 32 infants failed HHFNC (Table 1). Infants who 
failed HHFNC had a lower mean birth weight (p=0.035), higher mean FiO2 at time of 
commencing HHFNC (p=0.004) and a higher incidence of positive blood culture up to 
the time of starting HHFNC (p=0.001).  They were also found to have a higher 
maximum flow rate at the time of starting HHFNC (p=0.004).  
 
Multivariate regression analysis of birth weight, positive blood cultures and FiO2 using 
failure of HHFNC as the outcome showed that the mean FiO2 at the time of starting 
HHFNC was independently significantly higher in the infants who failed (p<0.05) but 
neither birth weight nor a positive blood culture were significantly different between the 
failure and success groups.  A FiO2 > 28% predicted failure of HHFNC with a 
sensitivity of 73% and specificity of 61%.  
 
The mean gestational age was higher in the 32 infants who had HHFNC as a primary 
mode [32 (range 26-40) weeks] than those who had HHFNC as a step down from 
CPAP or MV [30 (23-41) weeks, p=0.016].The mean birth weight was also higher in 
infants who had HHFNC as a primary mode [1,805 (range 880 – 4,695) gms] than 
those who had HHFNC as a step down from CPAP or MV [1,470 (range 510 – 4,400) 
gms, p=0.04]. The mean corrected gestational age at starting HHFNC was not 
significantly different between the two groups [33 (range 27 – 44) weeks] versus [33 
(range 25 – 48) weeks, p=0.386]. The mean FiO2 at starting HHFNC was not 
significantly different between the two groups (0.27 (range 0.21 – 0.45) versus (0.29 
(range 25 – 48) weeks, p=0.532).       
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Our data suggest that failure of HHFNC therapy is more common in neonates with a 
higher FiO2 at the time of starting HHFNC.  Arguably, a higher oxygen requirement 
reflects higher underlying lung disease severity as ventilation to perfusion mismatch 
and the degree of the intrapulmonary right to left shunting correlate with the oxygen 
requirement (4).  The importance of this study is that we report that a higher FiO2 on 
starting HHFNC is associated with failure of HHFNC. Manley et al undertook a 
secondary analysis of a randomized trial comparing HHFNC and CPAP and reached 
similar conclusions (5). They, however, only used HHFNC as a primary mode of 
support at birth. In our study, we also assessed infants in whom HHFNC was used as a 
stepdown mode of support.   We should acknowledge limitations of our study which 
were that records of only 59% of the eligible infants were available and it was a 
retrospective analysis of non-randomised data. Nevertheless, our results highlight a 
subgroup of infants who might be unlikely to benefit from HHFNC and may inform entry 
criteria into randomized trials.   
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Table 1: Success versus failure on HHFNC post-extubation (for continuous data sets, results expressed as mean (range); for discrete data 
sets, NS = not significant).  
 Succeeded on HHFNC Failed on HHFNC P Value 
N 102 32  
Gestational age (GA) (weeks) 30.6 (23 – 41) 29.8 (24 – 39) 0.244 
Gender  Female = 39 
Male = 63 
Female = 12 
Male = 20 
NS 
Antenatal steroids received  None = 21 
Incomplete = 63 
Complete = 18 
None = 8 
Incomplete = 21 
Complete = 3 
NS 
Surfactant received Yes = 41 
No = 61 
Yes = 10 
No = 22 
NS 
IUGR Yes = 15 
No = 87 
Yes = 9 
No = 23 
NS 
Congenital anomalies Yes = 15 
No = 87 
Yes = 7 
No = 25 
NS 
Birth weight (g) 1603 (600 – 4694) 1376 (512 – 3146) 0.035 
Corrected GA (CGA) at starting HHFNC (weeks) 32.7 (27 – 48) 32.6 (25 – 39) 0.852 
HHFNC as primary mode 26 6 0.598 
HHFNC as step-down from CPAP/MV 75 27 0.598 
Weight at starting HHFNC (g) 1806 (760 – 4990) 1631 (668 – 3480) 0.137 
CPAP pressure (cmH2O) when switched to HHFNC 5.6 (4 – 8) 5.7 (4 – 7) 0.660 
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FiO2 at starting HHFNC 0.28 (0.21 – 0.60) 0.34 (0.21 – 0.59) 0.004 
CRP at starting HHFNC 8.8 (0 – 109) 6.7 (0 - 48) 0.875 
Flow rate (L/min) started on HHFNC 6.03 (3 – 8) 6.30 (4 – 8) 0.195 
Maximum flow rate (L/min)  6.18 (3 – 8) 6.83 (5 – 8) 0.004 
Duration of HHFNC (days)  10.9 (0 – 89) 9.7 (1 – 38) 0.739 
FiO2 at time failing HHFNC N/A 0.44 (0.21 – 1.00) N/A 
Patent ductus arteriosus (PDA) at time of starting HHFNC Yes = 5 
No = 97 
Yes = 4 
No = 28 
NS 
Caffeinated at time of starting HHFNC Yes = 66 
No = 36 
Yes = 20 
No = 12 
NS 
Blood culture at time of starting HHFNC Positive = 2 
Negative = 70 
No culture = 30 
Positive = 3 
Negative = 11 
No culture = 18 
0.001 
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